How much funding has Storm Therapeutics raised?

Storm Therapeutics has raised $119.4M in total funding, most recently a Series C round.

Who are Storm Therapeutics's investors?

Storm Therapeutics's investors include Pfizer Ventures, Cambridge Innovation Capital, M Ventures, Seroba Life Sciences, Imperial Innovations, Merck Life Sciences.

When was Storm Therapeutics founded?

Storm Therapeutics was founded in 2015.

Where is Storm Therapeutics headquartered?

Storm Therapeutics is headquartered in Cambridge, United States.

What industry is Storm Therapeutics in?

Storm Therapeutics operates in Biotech, Healthcare, Oncology.

How many employees does Storm Therapeutics have?

Storm Therapeutics has 11-50 employees.

Storm Therapeutics

Home | Harnessing the power of RNA epigenetics | Cambridge, UK

Cambridge, United States · Founded 2015 · $119.4M raised

Biotech

Healthcare

Oncology

Headquarters: Cambridge
Employees: 11–50
Founded: 2015
Business Model: B2B

Website: stormtherapeutics.com
Total Funding: $119.4M
Last Round: $56.0M Series CMay 2026
Rounds: 4

About

Storm Therapeutics is a clinical-stage biotechnology company founded in 2015 as a University of Cambridge spin-out, pioneering cellular reprogramming through RNA modifications to treat cancer, inflammation, viruses, and CNS diseases. Its drug discovery platform targets RNA-modifying enzymes to develop small molecule inhibitors, with lead program STC-15 currently in Phase 2 clinical trials for sarcoma.

Summary

Storm Therapeutics is a Biotech company based in Cambridge, United States, founded in 2015. It has raised $119.4M in total across 4 rounds, most recently a $56.0M Series C round in May 2026. Investors include Pfizer Ventures, Cambridge Innovation Capital and M Ventures.

LinkedIn X (Twitter)